Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study

Farhad Ravandi, Rita Assi, N. Daver, Christopher B. Benton, T. Kadia, Philip A. Thompson, Gautam Borthakur, Y. Alvarado, Elias J. Jabbour, Marina Konopleva, Koichi Takahashi, Steven Kornblau, Courtney D. DiNardo, Zeev Estrov, Wilmer Flores, Sreyashi Basu, J. Allison, Padmanee Sharma, Sherry Pierce, Allison PikeJorge E. Cortes, Guillermo Garcia-Manero, Hagop M. Kantarjian

Research output: Contribution to journalArticlepeer-review

33 Scopus citations

Fingerprint

Dive into the research topics of 'Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study'. Together they form a unique fingerprint.

Medicine & Life Sciences